news
75 percent of nanopharmaceuticals are being developed for oncology
A report states that three quarters of the roughly 230 nanopharmaceuticals in clinical development are for use as targeted cancer therapeutics.
List view / Grid view
Cancer
news
Chinese ABRAXANE® supply expected to be disrupted
The marketing agent for China, BeiGene, announced the China National Medical Products Administration (NMPA) suspended the importation, sales and use of ABRAXANE.
news
Mass cytometry could reveal best cancer drug regimens for clinical trials
Researchers have developed a new technology that could provide real-time analysis of patient samples during clinical trials to reveal the best cancer treatment regimens.
news
EMA begins safety review of ifosfamide cancer medicines
The EMA has announced the results of its pharmacovigilance meeting for March, saying that it has started a review of medicines containing ifosfamide due to a higher risk of encephalopathy.
news
Almost 400 cell and gene therapies in US pipeline, finds report
New research has found that there are 362 cell and gene therapies in clinical pipelines in the US, an increase from 2018.
news
Online pharmacy finds high levels of NDMA in metformin
Tests conducted by an online pharmacy has revealed high levels of NMDA in the diabetes drug metformin, prompting the company to press for a recall.
news
Gilead set to acquire Forty Seven for $4.9bn later in 2020
Gilead's acquisition of Forty Seven was unanimously approved by both companies' Boards of Directors, for $95.50 per share.
news
US drug prices rose three times faster than inflation since 2007
A study of over 602 brand-name prescription drugs shows that list prices increased over 1.5 times and net prices rose over 3.5 times inflation in the past decade.
news
Nanocarrier could revolutionise chemotherapy drug delivery
Scientists have developed an innovative nanocarrier that can selectively target and deliver a chemotherapy payload to cancer cells without adverse effects on healthy cells.
news
Oncology top area for non-industry sponsored clinical trials
Researchers have found that oncology therapies had the most investment in non-industry sponsored clinical trials last year.
news
Supersensitive smart material developed for targeted drug delivery
Scientists have developed a highly sensitive material that can analyse multiple environmental parameters simultaneously, which could be used in drug delivery.
article
Trends in the CDMO industry for 2020
Over the past decade, the pharmaceutical industry has witnessed rapid growth in outsourcing services, driven by various factors including the growth of small molecules, increasing API complexities and the need to optimise costs. Here, Peter DeYoung shares his thoughts on the key trends he expects to see in the contract…
news
FDA requests market withdrawal of weight-loss drug Belviq
After clinical trials showed an increased risk of cancer in patients taking Belviq, the FDA has recommended the withdrawal of the drug from the US market.
news
Insight into 2020’s clinical trials landscape
Oncology, industry-sponsored and a combination of the two, will account for the majority of clinical trials categories over the course of the coming year.
news
PhRMA report reveals nearly 600 drugs in US paediatric pipeline
New research from PhRMA found that in the US, there are almost 600 paediatric medicines in development in over 2,000 clinical trials.
